Side-by-side · Research reference

LiraglutidevsPT-141

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AFDA-ApprovedVerified14/45 cited

BFDA-ApprovedReviewed13/41 cited

Liraglutide

Daily GLP-1 RA · FDA-Approved

0.6–3.0 mgDaily doseSAXENDA (liraglutide) injectio 2014

5–10%Body-weight ↓SAXENDA (liraglutide) injectio 2014

~13 hrHalf-lifeSAXENDA (liraglutide) injectio 2014

SQ · Abdomen / thigh / arm · Once daily

PT-141

MC4R Agonist · FDA-Approved (HSDD)

1.75 mgPer doseVYLEESI (bremelanotide injecti 2019

Pre-sexTimingVYLEESI (bremelanotide injecti 2019

~2.7 hrHalf-lifeVYLEESI (bremelanotide injecti 2019

SQ · Abdomen / thigh · ≥45 min before sex

01Mechanism of Action

Parameter

Liraglutide

PT-141

Primary target

GLP-1 receptor (GLP-1R)SAXENDA (liraglutide) injectio 2014

Melanocortin-4 receptor (MC4R) in hypothalamusSimerly 2023 VYLEESI (bremelanotide injecti 2019

Pathway

GLP-1R agonism → ↑glucose-dependent insulin, ↓glucagon, ↓gastric emptying, ↓appetiteSAXENDA (liraglutide) injectio 2014 Marso 2016

MC4R agonism in paraventricular nucleus → autonomic + neuroendocrine sexual arousal pathwaysSimerly 2023

Downstream effect

Glycemic improvement, modest body-weight reduction, cardiovascular event reduction in high-risk T2DMarso 2016

Increased sexual desire and arousal; central rather than peripheral mechanismClayton 2015

Feedback intact?

Glucose-dependent insulin release preserves physiological feedback

—

Origin

Modified GLP-1(7-37) with Lys26 substitution (Arg34) and C-16 palmitoyl-glutamate acylation for albumin bindingSAXENDA (liraglutide) injectio 2014

Cyclic 7-AA peptide derived from α-MSH (agonist Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-OH cyclic)VYLEESI (bremelanotide injecti 2019

Antibody development

—

02Dosage Protocols

Parameter

Liraglutide

PT-141

Standard dose (T2D, Victoza)

1.2–1.8 mg / daySAXENDA (liraglutide) injectio 2014

—

Standard dose (weight, Saxenda)

3.0 mg / day (after 5-week titration)SAXENDA (liraglutide) injectio 2014

—

Frequency

Once daily, same time each day

PRN, max 8 doses / month

Titration schedule

0.6 → 1.2 → 1.8 → 2.4 → 3.0 mg over 5 weeks

Mitigates GI side effects.

—

Evidence basis

FDA-approved · Phase 3 RCTs (LEADER, SCALE)Marso 2016 SAXENDA (liraglutide) injectio 2014

FDA-approved (HSDD pre-menopausal women)VYLEESI (bremelanotide injecti 2019 Clayton 2015

Duration

Indefinite for chronic indication

PRN; reassess if no benefit after 8 doses

Reconstitution

Pre-filled commercial pen (no reconstitution)

Pre-filled commercial pen (Vyleesi). Research vial: bacteriostatic water.

Timing

Any time of day; consistent

≥45 min before sexual activity

Half-life

~13 hrSAXENDA (liraglutide) injectio 2014

~2.7 hrVYLEESI (bremelanotide injecti 2019

Standard dose

—

1.75 mg SQVYLEESI (bremelanotide injecti 2019

Single dose ≥45 min before anticipated sexual activity. Max 1 dose / 24 hr.

Lower / starter dose

—

1 mg (off-label)

04Side Effects & Safety

Parameter

Liraglutide

PT-141

GI symptoms

Nausea, vomiting, diarrhea (very common during titration)SAXENDA (liraglutide) injectio 2014

—

Pancreatitis risk

Rare; discontinue if suspected

—

Thyroid C-cell tumours

Boxed warning — contraindicated in MEN2 / MTC historySAXENDA (liraglutide) injectio 2014

—

Hypoglycemia

Low risk as monotherapy; elevated with sulfonylureas / insulin

—

Heart rate

Modest ↑ resting HR (~2-3 bpm)

—

Cardiovascular benefit

↓ MACE in high-risk T2D (LEADER trial)Marso 2016

—

Pregnancy / OB

Contraindicated

Nausea

—

Common (~40%); often transientVYLEESI (bremelanotide injecti 2019

Flushing

—

Common, transient

Injection site reaction

—

Erythema, mild pain

Headache

—

Common

Hyperpigmentation (focal)

—

Rare focal skin darkening; reversible after discontinuationVYLEESI (bremelanotide injecti 2019

Hypertension (transient)

—

Mean ↑6 mmHg systolic peaking ~4 h post-dose; resolves within 12 hVYLEESI (bremelanotide injecti 2019

Cardiovascular disease

—

Use caution; transient BP rise

Absolute Contraindications

Liraglutide

·MTC personal or family history; MEN2
·Pregnancy / breastfeeding
·Hypersensitivity to liraglutide

PT-141

·Uncontrolled hypertension
·Known cardiovascular disease (caution)
·Pregnancy

Relative Contraindications

Liraglutide

·Severe gastroparesis
·History of pancreatitis
·Severe gastrointestinal disease

PT-141

·Pre-existing hyperpigmentation disorders
·MC4R-pathway-dependent psychiatric conditions

05Administration Protocol

Parameter

Liraglutide

PT-141

1. Reconstitution / device

Commercial pre-filled pen, no reconstitution required.

Vyleesi: pre-filled auto-injector. Research vial: 2 mL bacteriostatic water per 10 mg → 5 mg/mL.

2. Injection site

SQ — abdomen, thigh, or upper arm. Rotate sites.

SQ — abdomen or thigh.

3. Timing

Once daily, same time each day. Take with or without food.

≥45 min before sexual activity for peak effect. Effect persists ~6–8 h.

4. Storage

Refrigerate 2–8 °C unopened; room temp ≤30 °C up to 30 days after first use.

Vyleesi: room temp ≤30 °C. Research vial: refrigerate after reconstitution.

5. Needle

Pen-supplied 32G needle.

Auto-injector (Vyleesi) or 29–31G, 4–8 mm insulin syringe.